Immune Score Based Radiomics in Nasopharyngeal Carcinoma

In nasopharyngeal carcinoma (NPC), tumor, node and metastasis (TNM) staging system is the main tool for determining treatment strategy and assessment of prognosis. However, the prognoses of patients with the same TNM stage after similar treatment vary widely. The aim of this study is to establish an immune score based radiomic staging system for NPC.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Nasopharyngeal Carcinoma Carcinoma Head and Neck Neoplasms Nasopharyngeal Diseases Nasopharyngeal Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial Otorhinolaryngologic Diseases Otorhinolaryngologic Neoplasms Pharyngeal Diseases Pharyngeal Neoplasms Stomatognathic Diseases

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Renmin Hospital of Wuhan University, Wuhan, Hubei, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with newly histologically confirmed non-keratinizing/keratinizing carcinoma.

ECOG Performance status: 0-1 With normal liver function test (ALT, AST ≤2.5ULN) Renal: creatinine clearance ≥60ml/min Without hematopathy,marrow: WBC >4*109/L, HGB>90G/L, and PLT>100*109/L. Written informed consent

Exclusion criteria

Contraindications for MRI scan Prior malignancy (except adequately treated carcinoma in-situ of the cervix or · basal/squamous cell carcinoma of the skin) Previous chemotherapy or radiotherapy (except non-melanomatous skin cancers outside the intended RT treatment volume) Patient is pregnant or lactating Any severe intercurrent disease, which may bring unacceptable risk or affect the compliance of the trial, for example, unstable cardiac disease requiring treatment, renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose >1.5×ULN), or emotional disturbance.

Treatment and study plan

Immune Score Based Radiomics

Diagnostic Test

To establish an immune score based radiomic staging system for nasopharyngeal carcinoma

Primary outcomes

Area Under Curve (AUC)

Time frame: Median follow-up time of 5 years for the whole group

The AUC of the immune score based radiomic staging system

Study contacts

Contact information is provided by the study sponsor or research team.

Xiaozhong Chen

CONTACT

[email protected]

0571-88128202 ext. +86

Sponsors and collaborators

Lead sponsor

Zhejiang Cancer Hospital

Other

Collaborators

First Affiliated Hospital of Wenzhou Medical University
Ningbo Medical Center Lihuili Hospital
Ningbo No. 1 Hospital
Renmin Hospital of Wuhan University

Registry information

Official study title

Immune Score Based Radiomics in Nasopharyngeal Carcinoma (IMRAN Study)

Important dates

Study start: 2021
Primary completion: 2022
Study completion: 2027
First posted: Nov 18, 2021
Registry last updated: Nov 18, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting